HealthTree Logo
search more_vert
close
person Sign In / Create Account

The diagnosis of BPDCN involves a combination of blood tests, bone marrow tests, and imaging tests. The following sections detail the specific tests used in diagnosing BPDCN.

Blood Tests:

  • Complete blood count (CBC): This test measures the amount of different types of cells in the blood. In BPDCN, there may be an increase in the number of white blood cells and a decrease in the number of red blood cells and platelets.

Bone Marrow Tests:

  • Bone marrow aspiration and biopsy: These tests involve taking a small sample of bone marrow from the hip bone and examining it under a microscope. The presence of BPDCN cells in the bone marrow can confirm the diagnosis.
  • Immunohistochemistry: This test uses antibodies to detect specific proteins on the surface of cells in the bone marrow sample. A diagnosis of BPDCN is made when there is the presence of CD123, CD4, CD56 and TCL-1 in the absence of other myeloid leukemia markers, particularly myeloperoxidase and lysozyme.
  • Flow cytometry: This test is used to identify the specific type of cells present in the blood. In BPDCN, the malignant cells usually express certain markers such as CD4, CD56, and CD123.
  • Cytogenetic analysis: This test looks for certain changes in the chromosomes of the cancer cells. Some patients with BPDCN may have specific chromosomal abnormalities.

Imaging Tests:

  • Computed Tomography (CT) scan: This test uses x-rays to create detailed images of the inside of the body. It can help identify any tumors or areas of cancer spread.
  • Positron Emission Tomography (PET) scan: This test uses a small amount of radioactive glucose to find cancer cells in the body. It can help determine the extent of the disease.

A Summary of Diagnosing Blastic Plasmacytoid Dendritic Cell Neoplasm

It's important to note that the diagnosis and classification of BPDCN is complex and requires a comprehensive evaluation by a team of specialists. A complete diagnosis requires a physical examination, looking at a bone marrow sample under the microscope, immunophenotyping, and often molecular genetic testing. The specific markers and genetic changes found in the bone marrow sample can also help determine a person's prognosis and guide treatment decisions. If you don't currently have a BPDCN specialist on your team, it is important that you consult with one. Use HealthTree's BPDCN Specialist Directory to locate a specialist near you. 

Want to Learn More About Blastic Plasmacytoid Dendritic Cell Neoplasm?

Keep reading HealthTree for Blastic Plasmacytoid Dendritic Cell Neoplasm's 101 pages!

The diagnosis of BPDCN involves a combination of blood tests, bone marrow tests, and imaging tests. The following sections detail the specific tests used in diagnosing BPDCN.

Blood Tests:

  • Complete blood count (CBC): This test measures the amount of different types of cells in the blood. In BPDCN, there may be an increase in the number of white blood cells and a decrease in the number of red blood cells and platelets.

Bone Marrow Tests:

  • Bone marrow aspiration and biopsy: These tests involve taking a small sample of bone marrow from the hip bone and examining it under a microscope. The presence of BPDCN cells in the bone marrow can confirm the diagnosis.
  • Immunohistochemistry: This test uses antibodies to detect specific proteins on the surface of cells in the bone marrow sample. A diagnosis of BPDCN is made when there is the presence of CD123, CD4, CD56 and TCL-1 in the absence of other myeloid leukemia markers, particularly myeloperoxidase and lysozyme.
  • Flow cytometry: This test is used to identify the specific type of cells present in the blood. In BPDCN, the malignant cells usually express certain markers such as CD4, CD56, and CD123.
  • Cytogenetic analysis: This test looks for certain changes in the chromosomes of the cancer cells. Some patients with BPDCN may have specific chromosomal abnormalities.

Imaging Tests:

  • Computed Tomography (CT) scan: This test uses x-rays to create detailed images of the inside of the body. It can help identify any tumors or areas of cancer spread.
  • Positron Emission Tomography (PET) scan: This test uses a small amount of radioactive glucose to find cancer cells in the body. It can help determine the extent of the disease.

A Summary of Diagnosing Blastic Plasmacytoid Dendritic Cell Neoplasm

It's important to note that the diagnosis and classification of BPDCN is complex and requires a comprehensive evaluation by a team of specialists. A complete diagnosis requires a physical examination, looking at a bone marrow sample under the microscope, immunophenotyping, and often molecular genetic testing. The specific markers and genetic changes found in the bone marrow sample can also help determine a person's prognosis and guide treatment decisions. If you don't currently have a BPDCN specialist on your team, it is important that you consult with one. Use HealthTree's BPDCN Specialist Directory to locate a specialist near you. 

Want to Learn More About Blastic Plasmacytoid Dendritic Cell Neoplasm?

Keep reading HealthTree for Blastic Plasmacytoid Dendritic Cell Neoplasm's 101 pages!

Get the latest thought leadership on Blastic Plasmacytoid Dendritic Cell Neoplasm delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Blastic Plasmacytoid Dendritic Cell Neoplasm Newsletter" for Blastic Plasmacytoid Dendritic Cell Neoplasm news, life with Blastic Plasmacytoid Dendritic Cell Neoplasm stories, Blastic Plasmacytoid Dendritic Cell Neoplasm clinical trials, Blastic Plasmacytoid Dendritic Cell Neoplasm 101 articles and events with Blastic Plasmacytoid Dendritic Cell Neoplasm experts.